Prospective comparison of whole-body MRI and 68 Ga-PSMA PET/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy

Published on Mar 16, 2019in European Journal of Nuclear Medicine and Molecular Imaging7.081
· DOI :10.1007/S00259-019-04308-5
Lino M. Sawicki15
Estimated H-index: 15
,
Julian Kirchner13
Estimated H-index: 13
+ 13 AuthorsHubertus Hautzel26
Estimated H-index: 26
Sources
Abstract
Purpose To assess whole-body magnetic resonance imaging (wb-MRI) for detection of biochemical recurrence in comparison to 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography (68Ga-PSMA PET/CT) in prostate cancer (Pca) patients after radical prostatectomy.
📖 Papers frequently viewed together
44 Citations
50 Citations
14 Citations
References40
Newest
#2Priscilla Guglielmo (University of Milan)H-Index: 5
Last. Maria PicchioH-Index: 59
view all 11 authors...
Purpose The main drawback of 11C-choline PET/CT for restaging prostate cancer (PCa) patients with biochemical failure is the relatively low positive detection rate for prostate specific antigen (PSA) < 1 ng/ml. This study assessed whether 11C-choline PET/CT predicts survival in PCa patients with PSA < 1 ng/ml.
6 CitationsSource
Purpose We studied the usefulness of 68Ga-prostate-specific membrane antigen (PSMA) PET/CT for detecting relapse in a prospective series of patients with biochemical recurrence (BCR) of prostate cancer (PCa) after radical treatment.
44 CitationsSource
#1Eric Ka-Chai Lee (Tuen Mun Hospital)H-Index: 7
#2W H Mui (Tuen Mun Hospital)H-Index: 1
Last. Fcs Wong (Tuen Mun Hospital)H-Index: 2
view all 5 authors...
INTRODUCTION: Salvage radiotherapy (SRT) provides effective biochemical control for patients with prostate cancer who have prostate specific antigen (PSA) failure after radical prostatectomy. However, the effect of SRT on long-term clinical outcomes remains unknown. Therefore, we report the natural history of patients treated with SRT. METHODS: We identified 84 Chinese patients with prostate cancer treated with SRT to the prostatic fossa alone during 2006-2017 at Tuen Mun Hospital, Hong Kong. Su...
1 CitationsSource
Abstract Diagnosis and management of prostate cancer post treatment is a large and complex problem, and care of these patients requires multidisciplinary involvement of imaging, medical, and surgical specialties. Imaging capabilities for evaluation of men with recurrent prostate cancer are rapidly evolving, particularly with PET and MRI. At the same time, treatment options and capabilities are expanding and improving. These recommendations separate patients into three broad categories: (1) patie...
8 CitationsSource
#1Ahmed Eissa (Tanta University)H-Index: 8
#2Ahmed Elsherbiny (Tanta University)H-Index: 4
Last. Giampaolo Bianchi (University of Modena and Reggio Emilia)H-Index: 30
view all 13 authors...
INTRODUCTION: Recurrence after primary treatment of prostate cancer is one of the major challenges facing urologists. Biochemical recurrence is not rare and occurs in up to one third of the patients undergoing radical prostatectomy. Management of biochemical recurrence is tailored according to the site and the burden of recurrence. Therefore, developing an imaging technique to early detect recurrent lesions represents an urgent need. Positron emission tomography (PET) of 68Ga-labelled prostate-s...
32 CitationsSource
#1Paul Roach (RNSH: Royal North Shore Hospital)H-Index: 22
#2Roslyn J. FrancisH-Index: 22
Last. Andrew M. Scott (Austin Hospital)H-Index: 87
view all 15 authors...
: 68Ga-PSMA PET/CT scanning has been shown to be more sensitive than conventional imaging techniques in patients with prostate cancer. This prospective Australian multicenter study assessed whether 68Ga-PSMA PET/CT imaging affects management intent in patients with primary or recurrent prostate cancer. Methods: Before undertaking 68Ga-PSMA PET imaging, referring medical specialists completed a questionnaire detailing relevant demographic and clinical data as well as their proposed management pla...
184 CitationsSource
#1Lukas Hendrik EschH-Index: 2
#2Melanie Fahlbusch (Bethesda Hospital)H-Index: 1
Last. Volker Müller-Mattheis (HHU: University of Düsseldorf)H-Index: 11
view all 5 authors...
Objectives To evaluate, in a prospective study, the effectiveness of computed tomography (CT)-matched 11C-acetate (AC) positron-emission tomography (PET) in patients with prostate cancer (PCa) who had prostate-specific antigen (PSA) relapse after radical prostatectomy (RP) or radiotherapy (RT). Patients and Methods In 103 relapsing patients after RP (n = 97) or RT (n = 6) AC-PET images and CT scans were obtained. In patients with AC-PET-positive results with localized PCa recurrence, detected le...
5 CitationsSource
#1Julian KirchnerH-Index: 13
#2Benedikt Michael Schaarschmidt (Forschungszentrum Jülich)H-Index: 1
Last. Christian BuchbenderH-Index: 25
view all 9 authors...
To investigate the physiologic Ga-PSMA distribution and evaluate focal or diffuse radiotracer uptake in nonprostate cancer malignancies and in incidental findings.Ga-PSMA PET/CT scans in 55 men performed for prostate cancer (49) or renal cell carcinoma (6) staging were analyzed retrospectively. Two radiologists evaluated the datasets in 2 reading sessions. First, physiological Ga-PSMA uptake was evaluated. Second, scans were analyzed for incidental uptake. SUVmax and SUVmean were recorded. Other...
21 CitationsSource
#1Felix DietleinH-Index: 15
#2Carsten KobeH-Index: 30
Last. Markus DietleinH-Index: 46
view all 12 authors...
: Several studies outlined the sensitivity of 68Ga-labeled PET tracers against the prostate-specific membrane antigen (PSMA) for localization of relapsed prostate cancer in patients with renewed increase in the prostate-specific antigen (PSA), commonly referred to as biochemical recurrence. Labeling of PSMA tracers with 18F offers numerous advantages, including improved image resolution, longer half-life, and increased production yields. The aim of this study was to assess the PSA-stratified per...
90 CitationsSource
#1Ali Afshar-Oromieh (University Hospital Heidelberg)H-Index: 37
#2Tim Holland-Letz (DKFZ: German Cancer Research Center)H-Index: 27
Last. Uwe Haberkorn (University Hospital Heidelberg)H-Index: 85
view all 16 authors...
Purpose Since the clinical introduction of 68Ga-PSMA-11 PET/CT, this imaging method has rapidly spread and is now regarded as a significant step forward in the diagnosis of recurrent prostate cancer (PCa). The aim of this study was to analyse the influence of several variables with possible influence on PSMA ligand uptake in a large cohort.
321 CitationsSource
Cited By27
Newest
#1Thomas Ng (Harvard University)H-Index: 26
#2Xin Gao (Harvard University)
Last. Sophia C. Kamran (Harvard University)H-Index: 16
view all 6 authors...
Recent developments in prostate-specific membrane antigen (PSMA) targeted imaging and therapeutics (theranostics) promise to revolutionize the management of primary, biochemically recurrent, and metastatic prostate cancer. In order to maximize the clinical impact of PSMA-targeted theranostics, a coordinated approach between the clinical stakeholders involved in prostate cancer management is required. Here, we present a vision for multidisciplinary use of PSMA theranostics from the viewpoints of ...
Source
#1Muhammad Junaid Niaz (Cornell University)H-Index: 6
#2Michael Sun (Cornell University)H-Index: 4
Last. Elisabeth O'Dwyer (Cornell University)
view all 7 authors...
Abstract null null 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) underperforms in detecting prostate cancer (PCa) due to inherent characteristics of primary and metastatic tumors, including relatively low rate of glucose utilization. Consequently, alternate PCa PET imaging agents targeting other aspects of PCa cell biology have been developed for clinical practice. The most common dedicated PET imaging tracers include 68Ga/18F prostate-specific membrane antigen (PSMA), 11C-Cholin...
Source
#2Rudolf A. Werner (MHH: Hannover Medical School)H-Index: 23
177Lu-Prostate-specific membrane antigen (PSMA)-radioligand therapy (RLT) is a promising treatment option in patients with metastatic castration-resistant prostate cancer (mCRPC). We aimed to determine the predictive value of pretherapeutic PSMA-ligand positron emission tomography (PET) and established clinical parameters for early biochemical response after two cycles of RLT. In total, 71 mCRPC patients who had undergone PET/computed tomography (CT) with 68Ga-PSMA-11 prior to two cycles of 177L...
1 CitationsSource
#1Randall Brenneman (WashU: Washington University in St. Louis)H-Index: 16
#2Brian C. Baumann (WashU: Washington University in St. Louis)H-Index: 16
Last. Jeff M. Michalski (WashU: Washington University in St. Louis)H-Index: 73
view all 3 authors...
1 CitationsSource
#1Yuefu Zhan (Sichuan University)
#3Mingliang Li (Sichuan University)
Purpose: A recent meta-analysis in patients with non-small cell lung cancer showed no difference between whole-body magnetic resonance imaging (WBMRI) and positron emission tomography/computed tomography (PET/CT), but no such study is available for prostate cancer (PCa). This study aimed to compare WBMRI and PET/CT for bone metastasis detection in patients with PCa. Materials and methods: PubMed, Embase, and the Cochrane library were searched for papers published up to April 2020. The population...
Source
#1Haoli Yin (NU: Nanjing University)
#2Mengxia Chen (NU: Nanjing University)H-Index: 6
Last. Hongqian Guo (NU: Nanjing University)H-Index: 21
view all 13 authors...
Purpose Prostate-specific membrane antigen (PSMA) positron emission tomography (PSMA-PET) is an ideal tool for staging and restaging of prostate cancer (PCa). This study was designed to investigate the prognostic role of preoperative 68Ga-PSMA-11 PET/CT in predicting pathological upgrading from multiparametric magnetic resonance imaging-targeted biopsy (mpMRI-TB) to final radical prostatectomy (RP) specimens in patients with localized PCa. Methods A total of 67 biopsy-confirmed localized PCa pat...
1 CitationsSource
#1Kobika Sritharan (The Royal Marsden NHS Foundation Trust)H-Index: 1
#2Romelie Rieu (The Royal Marsden NHS Foundation Trust)H-Index: 1
Last. Alison Tree (The Royal Marsden NHS Foundation Trust)H-Index: 20
view all 3 authors...
There has been growing interest in oligometastatic prostate cancer (OMPC) with a mounting body of evidence to suggest that it is a distinct disease state, both biologically and prognostically, when compared to polymetastatic prostate cancer. Three subgroups have been recognised; de novo synchronous, metachronous/oligorecurrent and oligoprogressive disease. The belief that patients with OMPC can be treated more aggressively to improve survival is transforming patient care. Identifying these patie...
1 CitationsSource
#1Andrea Farolfi (UNIBO: University of Bologna)H-Index: 8
#2Boris Hadaschik (University of Duisburg-Essen)H-Index: 56
Last. Stefano Fanti (UNIBO: University of Bologna)H-Index: 83
view all 9 authors...
Abstract Context Next-generation imaging includes positron emission tomography (PET) imaging and whole-body magnetic resonance imaging (wbMRI) including diffusion-weighted imaging. Accurate quantification of oligometastatic disease using next-generation imaging is important to define the role and value of metastasis-directed therapy (MDT). Objective To perform a review of next-generation imaging modalities in the detection of recurrent oligometastatic hormone-sensitive prostate cancer in men who...
1 CitationsSource
#1Soichiro Yoshida (Tokyo Medical and Dental University)H-Index: 29
#2Taro Takahara (Tokai University)H-Index: 27
Last. Yasuhisa Fujii (Tokyo Medical and Dental University)H-Index: 49
view all 6 authors...
The diffusion-weighted imaging signal is derived from the motion of water molecules. It represents the physiological characteristics of tissue and is an essential imaging sequence for prostate cancer. Whole-body diffusion-weighted imaging facilitates the assessment of pathological conditions throughout the body. The concept of diffusion-weighted whole-body imaging with background body signal suppression and technological advances has led to routine clinical deployment of whole-body diffusion-wei...
2 CitationsSource
#1Ping LiH-Index: 2
#2Chang Liu (Fudan University)H-Index: 5
Last. Qing ZhangH-Index: 2
view all 14 authors...
Purpose The purpose of this study was to assess the potential of 99mTc-labeled PSMA-SPECT/CT and diffusion-weighted image (DWI) for predicting treatment response after carbon ion radiotherapy (CIRT) in prostate cancer. Patients and Methods We prospectively registered 26 patients with localized prostate cancer treated with CIRT. All patients underwent 99mTc-labeled PSMA-SPECT/CT and multiparametric magnetic resonance imaging (MRI) before and after CIRT. The tumor/background ratio (TBR) and mean a...
Source